The company intends to use the net proceeds from the offering for funding of ongoing operations, including clinical development of existing product candidates, and for working capital and other general corporate purposes.
The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
Shares +5% at $0.95 after hours.